Loading...
OTC Markets
Totals
Securities
12,312
Dollar Vol
$1.5B
Share Vol
2.7B
Trades
270,267

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

BPTH
Bio-Path Holdings, Inc.

Common Stock

0.1652

-0.00278

-1.65%

0.1652 / 0.1699 (5000 x 15000)

Real-Time Best Bid & Ask: 12:32pm 07/14/2025
Delayed (15 Min) Trade Data: 02:08pm 07/14/2025

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard

Suite 210

Bellaire, TX 77401

Business Description
Bio-Path is a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs.
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001133818
Fiscal Year End
12/31
Company Officers & Contacts
Anthony Price
Vice President

William R. Rohrlich, II
Legal Counsel

Board of Directors
Douglas P. Morris
Chairman

Paul Aubert
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
Ernst & Young LLP

250 South Australian Avenue

Suite 900

West Palm Beach, FL 33401

Investment Bank
H.C. Wainwright & Co., LLC

430 Park Avenue, 3rd Floor

New York, NY 10022

Investor Relations/Marketing/Communications
Stern IR, Inc.

19 West 87th Street

Suite 400

New York, NY 5000

Securities Counsel
Winstead PC

2728 N. Harwood Street

Dallas, TX 75201

Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US, 2007
Employees
10 as of 03/07/2024
Shell
No
Products and Services

We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.

Company Facilities

In April 2014, we entered into a lease agreement for approximately 3,000 square feet of office space for general and administrative purposes in Bellaire, Texas, which is part of the Houston metropolitan area. The term of the lease began on August 1, 2014 and was scheduled to terminate on July 31, 2019. In May 2019, we entered into an amendment to the lease agreement to extend the term of the lease to October 31, 2024. In October 2024, we entered into a second amendment to the lease agreement to extend the term of the lease to October 31, 2025. In April 2016, we entered into a lease agreement for approximately 2,100 square feet of lab space located in Bellaire, Texas for research and development purposes. The term of the lease began on May 1, 2016 and was scheduled to terminate on April 30, 2019. In December 2018, we entered into an amendment to the lease agreement to extend the term of the lease to April 30, 2022. In January 2022, we exercised an option in the lease agreement amendment to extend the term of the lease to April 30, 2025. We do not own or lease any other real property that is materially important to our business. We believe that our current facilities are adequate for our current needs and that additional space will be available when and as needed.

Company Notes
Formerly=Ogden Golf Co. Corp. until 2-2008
OTCQB Venture Market Logo
Joined OTCQB 02/2025
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.